Over the past decade, there has been a gradual uptick in the popularity of decentralized clinical trials (DCTs)—a trend that has accelerated dramatically due to Covid-19. Now, there will be no going back, largely for patients. “Patient-centricity” is more than an industry buzzword; it is a form of enlightened self-interest for sponsors and researchers. By minimizing the burden of participating in a clinical trial, sponsors simplify recruitment and increase retention and compliance. Study effectiveness is amplified and drugs get to market faster, saving patient lives and sponsor money.